Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome

Authors

  • Ali Bahari Gastroenterology and Hepatology Research Center. Mashhad University of Medical Sciences & Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Abbas EsmaeilZadeh Gastroenterology and Hepatology Research Center. Mashhad University of Medical Sciences & Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Azita Ganji Gastroenterology and Hepatology Research Center. Mashhad University of Medical Sciences & Department of Gastroenterology and Hepatology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Donya Farrokh Tehrani Radiology Department, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Mehdi Delghandi Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Zohreh Mousavi Endocrine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:

Background: Metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD) is a common public health problem. Visfatin is secreted by visceral adipose tissue and is an adipocytokine. It could be a pro-inflammatory adipocytokine and is related to the metabolic syndrome and non-alcoholic fatty liver disease. This study&nbsp;evaluated the association between visfatin levels in patients with the metabolic syndrome with and without non-alcoholic fatty liver disease (NAFLD). &nbsp;&nbsp; Methods:&nbsp;In this cross-sectional study, 120 patients with metabolic syndrome were selected. They were categorized into two groups, patients with fatty liver (n=70) and without fatty liver disease (n=50).&nbsp;Laboratory and anthropometric options such as age, sex, systolic blood pressure, fasting blood&nbsp;sugar,&nbsp;lipid profile, liver enzymes, uric acid, visfatin, insulin, BMI, waist circumference, and&nbsp;TNF-&alpha;&nbsp;were measured.&nbsp;The chi-square test, Mann-Whitney, t test, Spearman and Pearson correlations were used for the data analysis. &nbsp;&nbsp; Results:&nbsp;There was a significant difference between the fatty liver and non-fatty liver disease with visfatin,&nbsp;BMI, FBS and&nbsp;lipid profile (p<0.05).&nbsp;The mean&plusmn;SD level of visfatin was 37.1&plusmn;1.7 ng/dl in the non-fatty liver and was 44.4&plusmn;1.5 ng/dl in fatty liver participants (p=0.02). 59% of patients with metabolic syndrome had fatty liver in ultrasonography. &nbsp;&nbsp; Conclusion: According to this study, there was a correlation between visfatin levels and fatty liver disease.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Association of lifestyle with metabolic syndrome and non-Alcoholic fatty liver in children and adolescence

Introduction: Identification of the factors related to non-alcoholic fatty liver disease in children and adolescents help us to know appropriate methods for prevention and control of chronic diseases. Methods: This cross-sectional and analytic study comprised 962 children and adolescents, aged 6-18 years, in Isfahan in 2008. Variables related to life style and metabolic syndromes related...

full text

Metabolic syndrome and non-alcoholic fatty liver disease

Manuscript received and accepted: 26 September 2008 Abstract The development of nonalcoholic fatty liver disease (NAFLD) is strongly associated with the metabolic syndrome as reflected by the fact that approximately 90% of the patients with NAFLD have more than one feature of metabolic syndrome and about 33% have three or more criteria. The physiopathology, epidemiology and therapeutic consider...

full text

iron status and metabolic syndrome in patients with non-alcoholic fatty liver disease

background: a hypothesis has been presented about the role of serum iron, ferritin and transferrin saturation among patients with non-alcoholic fatty liver disease (nafld) and resistance to insulin (metabolic syndrome [mets]), but there is much controversy. this study aimed at investigating the level of serum iron and demographic characteristics in patients with nafld with or without mets. meth...

full text

Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome

Submit Manuscript | http://medcraveonline.com obesity, metabolic syndrome (MetS) or type 2 diabetes mellitus (T2DM). Histological manifestations of NAFLD vary from isolated steatosis to steatohepatitis (NASH), which is characterized by liver necroinflammation and ballooning with or without liver fibrosis, and finally cirrhosis; in some cases NASH may progress to hepatocellular carcinoma [4]. Da...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 31  issue 1

pages  167- 170

publication date 2017-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023